| CAS NO: | 1042224-63-4 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 5mg | 电议 |
| 50mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Cas No. | 1042224-63-4 |
| 别名 | 环巴胺抑制剂1 |
| 化学名 | 6-imidazo[1,2-a]pyridin-3-yl-N-piperidin-4-ylpyridin-2-amine |
| Canonical SMILES | C1CNCCC1NC2=CC=CC(=N2)C3=CN=C4N3C=CC=C4 |
| 分子式 | C17H19N5 |
| 分子量 | 293.37 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 35 nM for IRAK-4 The interleukin-1 receptor associated kinase (IRAK) family is comprised of four family members IRAK-1, IRAK-2, IRAK-3/M, and IRAK-4. Upon activation of their upstream cognate receptors, IRAK-4 is thought to phosphorylate IRAK-1 resulting in the activation and autophosphorylation of IRAK-1 an subsequent phosphorylation of downstream substrates. IRAK inhibitor 1 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4). In vitro: The regioisomeric pyridines IRAK inhibitor 1 (6) and it analogue (7) showed contrasting SAR, with the 2,6-pyridine isomer IRAK inhibitor 1 having low-nanomolar potency whilst the 2,4-pyridine isomer 7 showed little activity, despite having a more accessible bidentate-binding motif. At 10 μM, IRAK inhibitor 1 was found to have 39% inhibition for JNK-1 and 15% inhibition for JNK-2, respectivley [1]. In vivo: No animal in-vivo data available currently IRAK inhibitor 1 and its analogues. Clinical trial: IRAK inhibitor 1 is currently in the preclinical development stage and no clinical data are available. Reference: |
m.cnreagent.com